There are over 50 cannabis companies in Isreal that are involved in the cultivation, processing, and distribution of medical cannabis. Over the past few years, hundreds of millions of dollars have been invested into the development of a commercial industry of medical marijuana in Isreal.
Cannabis businesses operated under the assumption that the Prime Minster would keep his word, allowing companies to begin exporting medical cannabis around the world. However, Benjamin Netanyahu was persuaded by the United States President Donald Trump, to change his mind which halted the countries plans for exports.
This stalemate has caused doubt in the minds of cannabis business owners in Isreal, which now has caused companies to look outside of the country to keep their businesses alive.
Kanabo Research is a cannabis technology company in Isreal that develops, medically validates, and patents formulations of medical cannabis extracts designed to target specific Central Nervous System (CNS) disorders. The company has already announced a partnership with companies in Europe and Oregon which it plans to farm out its technology out to.
By continuing this stalemate, the Israeli Prime Minister is hurting the Israeli people who now are losing out on graining from an estimated $285M-$1.14B export industry.
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…